Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

shutterstock_212432119

LMTX fails Phase III trial, monotherapy benefits seen

July 28, 2016 Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure

TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …
News
sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016 Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
News
johnnolech

John Lechleiter to step down as Lilly CEO

July 27, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter

Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …
News

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016 Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
News
shutterstock_87495637

Orkambi deemed not suitable for NHS use

July 27, 2016 Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis

The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …
News

Pharma unit helps boost profits at Bayer

July 27, 2016 Research and Development, Sales and Marketing Bayer, Q2, results

The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
News
headquarters_2_web

Eli Lilly Q2 2016 results surpass estimates

July 27, 2016 Research and Development, Sales and Marketing Eli Lilly, financial report

Eli Lilly has released its financial report for the second quarter of 2016, noting a number of promising results.  The …
News
money_pills_2

Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals

July 27, 2016 Research and Development phase III, prostate cancer, tokai pharmaceuticals

Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …
News

GSK announces significant post-Brexit UK investment

July 27, 2016 Manufacturing and Production, Research and Development GSK, UK, brexit, investment

GlaxoSmithKline has given the UK life sciences industry a major boost in the post-Brexit landscape with an announcement that £275 …
News
ian_campbell

Innovate UK appoints first director of Health and Life Sciences

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ian Campbell, Innovate UK, appointment, health and life sciences

Ian Campbell has been named by Innovate UK as its first director for Health and Life Sciences. Innovate UK is …
Appointment
cq5dam

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016 Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …
News
celgene_1_02

Celgene’s Revlimid fails to improve overall survival from lymphoma in Phase III trial

July 26, 2016 Research and Development Celgene, Revlimid, lymphoma

Celgene has announced the publication of data from a Phase III trial investigating Revlimid (lenalidomide) in diffuse large B-cell lymphoma …
News

BMS names Fouad Namouni as new oncology development head

July 26, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Erbitux, Fouad Namouni, Taxol, Yervoy, appointment, opdivo

Bristol-Myers Squibb has announced the appointment of Fouad Namouni to the position of oncology development head, effective July 25, 2016. …
Appointment
gilead-sciences

Gilead lowers full-year guidance as sales and profits down in Q2

July 26, 2016 Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results

Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
News
janssen_latest_logo_on_sign_closer

Darzalex receives breakthrough designation in multiple myeloma from FDA

July 26, 2016 Manufacturing and Production, Research and Development FDA, Genmab, Janssen, darzalex, multiple myeloma

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Darzalex (daratumumab) in combination with standard of …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025